Lavish windfall gains from biotechnological unicorns
LOW RISK for entreprises
-
Fragmentation
-
Internationalization
-
Capital Intensity
-
Profitability
-
Fragmentation
-
Internationalization
-
Capital Intensity
-
Profitability

- Medicine demand bolstered by growing middle classes in Emerging Markets and aging population as a whole
- Resilience of drug spending irrespective of economic cycle, coupled with huge public support for improving people’s healthcare needs
- High level of R&D expenditure well covered by strong cash generation amid the pressing need for Covid-19 vaccines to reach herd immunity worldwide
- mRNA technology close to being a game-changer for the sector, especially in oncology treatments
- Venture capitalists and public investors’ appetite for investing in (listed) biotechnology firms

- Supply-chain disruptions due to states’ pressure to ‘reshore’ drug production within Western countries
- Lengthy procedures for new drug approvals on top of stiff price regulations
- Generic drug makers plagued with lower profit margins and higher debt gearing than patented drug ones
- Limited production capacities making it difficult to meet urgent delivery needs of all Covid-19 vaccines worldwide
- Bargaining power of India and China regarding vaccine production and delivery
Key players
Country | Role | Sector risk |
---|---|---|
![]() |
#1 market by revenue |
A
Low risk |
![]() |
#2 market by revenue |
B
Medium risk |
![]() |
#3 market by revenue |
A
Low risk |
![]() |
#4 market by revenue |
A
Low risk |
![]() |
#5 market by revenue |
A
Low risk |
LATEST NEWS ABOUT PHARMACEUTICALS
-
Sector vulnerability to rising financing costs
02 June
Five sectors stand out as the most exposed to financing stress: transportation, construction, hospitality, commodities and automotive.
-
Allianz Trade Global Survey 2023: Testing resilience
01 June
Roughly 70% of the nearly 3,000 companies we surveyed expect business turnover generated through exports to increase in 2023, against close to 80% in the 2022 edition.
-
European commercial real estate – selectivity matters!
25 May
The commercial real estate sector is getting squeezed by tightening financing conditions but prime assets have remained resilient.